Neupro (rotigotine) Disease Interactions
There are 5 disease interactions with Neupro (rotigotine):
Dopamine agonists (Includes Neupro) ↔ hypotension
Severe Potential Hazard, Moderate plausibility. Applies to: Hypotension
Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.
- "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.
- Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol 30 (1990): 194-9
- "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim, Ridgefield, CT.
- Hoehn MM "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol 32 (1975): 50-1
- "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.
Dopaminergic antiparkinson agents (Includes Neupro) ↔ psychosis
Severe Potential Hazard, Moderate plausibility. Applies to: Psychosis
Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.
Rotigotine (Includes Neupro) ↔ asthma
Moderate Potential Hazard, Moderate plausibility. Applies to: Asthma
Rotigotine (transdermal patch) contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life threatening or less severe asthmatic episodes in certain susceptible people. Sulfite sensitivity is seen more frequently in people with asthma than people without it.
Rotigotine (Includes Neupro) ↔ cardiovascular disease
Moderate Potential Hazard, Moderate plausibility. Applies to: Cardiovascular Disease
Some patients treated with rotigotine exhibited an increased pulse, greater than 100 beats per minute, while supine or standing. Also, like other dopaminergic agents, rotigotine might impair the systemic regulation of blood pressure causing postural/orthostatic hypotension, especially during dose escalation. These findings of blood pressure and heart rate elevations should be considered when treating patients with cardiovascular disease.
Rotigotine (Includes Neupro) ↔ fluid retention
Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure, Renal Dysfunction
Patients taking rotigotine had a higher incidence of weight gain associated with fluid retention, when compared with patients taking placebo. Weight gain and fluid retention should be monitored in patients using rotigotine, specially in those with concomitant illnesses as congestive heart failure and renal insufficiency.
Neupro (rotigotine) drug interactions
There are 594 drug interactions with Neupro (rotigotine)
Neupro (rotigotine) alcohol/food interactions
There is 1 alcohol/food interaction with Neupro (rotigotine)
More about Neupro (rotigotine)
- Neupro Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 42 Reviews
- Drug class: dopaminergic antiparkinsonism agents
- FDA Alerts (1)
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.